These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 29337597)

  • 61. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.
    el-Hazmi MA; al-Momen A; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F; Warsy AS
    Acta Haematol; 1995; 94(3):128-34. PubMed ID: 7502628
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Efficacy and safety of oral hydroxyurea in transfusion-dependent β-thalassaemia: a protocol for randomised double-blind controlled clinical trial.
    Yasara N; Wickramarathne N; Mettananda C; Manamperi A; Premawardhena A; Mettananda S
    BMJ Open; 2020 Oct; 10(10):e041958. PubMed ID: 33109679
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Relationship Between Some Single-nucleotide Polymorphism and Response to Hydroxyurea Therapy in Iranian Patients With β-Thalassemia Intermedia.
    Karimi M; Zarei T; Haghpanah S; Moghadam M; Ebrahimi A; Rezaei N; Heidari G; Vazin A; Khavari M; Miri HR
    J Pediatr Hematol Oncol; 2017 May; 39(4):e171-e176. PubMed ID: 28121747
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmacologic treatment of thalassemia intermedia with hydroxyurea.
    Hajjar FM; Pearson HA
    J Pediatr; 1994 Sep; 125(3):490-2. PubMed ID: 7520935
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment.
    Singer ST; Kuypers FA; Olivieri NF; Weatherall DJ; Mignacca R; Coates TD; Davies S; Sweeters N; Vichinsky EP
    Ann N Y Acad Sci; 2005; 1054():250-6. PubMed ID: 16339672
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A comprehensive study of immune function and immunophenotyping of white blood cells from β-thalassaemia/HbE patients on hydroxyurea supports the safety of the drug.
    Siriworadetkun S; Thiengtavor C; Thubthed R; Paiboonsukwong K; Fucharoen S; Pattanapanyasat K; Vadolas J; Svasti S; Chaichompoo P
    Br J Haematol; 2023 Feb; 200(3):367-376. PubMed ID: 36221231
    [TBL] [Abstract][Full Text] [Related]  

  • 67. An enhancer haplotype may influence BCL11A expression levels and the response to hydroxyurea in β-thalassemia patients.
    Maroofi N; Azarkeivan A; Banihashemi S; Mohammadparast S; Aghajanirefah A; Banan M
    Pharmacogenomics; 2017 Jul; 18(10):995-967. PubMed ID: 28639471
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.
    Rogers ZR
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):42-7. PubMed ID: 9317200
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
    Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
    Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Extramedullary hematopoiesis-related pleural effusion: the case of beta-thalassemia.
    Aessopos A; Tassiopoulos S; Farmakis D; Moyssakis I; Kati M; Polonifi K; Tsironi M
    Ann Thorac Surg; 2006 Jun; 81(6):2037-43. PubMed ID: 16731126
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Low and fixed dose of hydroxyurea is effective and safe in patients with HbSβ(+) thalassemia with IVS1-5(G→C) mutation.
    Dehury S; Purohit P; Patel S; Meher S; Kullu BK; Sahoo LK; Patel NK; Mohapatra AK; Das K; Patel DK
    Pediatr Blood Cancer; 2015 Jun; 62(6):1017-23. PubMed ID: 25546091
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
    Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
    Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Association of Exon 14 of the
    Mohammadi Z; Mohammadi R; Haghpanah S; Moghadam M; Pazhoomand R; Karimi M
    Hemoglobin; 2020 Nov; 44(6):406-410. PubMed ID: 33164584
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy and Safety of Hydroxyurea as Adjuvant Therapy in Pediatric Patients of Transfusion-Dependent Beta-Thalassemia Major at Zhob, Balochistan.
    Akram S; Khan Khattak SA; Khan MA
    Cureus; 2022 Jul; 14(7):e26691. PubMed ID: 35959173
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Hydroxyurea responses in clinically varied beta, HbE-beta thalassaemia and sickle cell anaemia patients of Eastern India.
    Chatterjee T; Chakravarty A; Chakravarty S
    Ann Hematol; 2018 May; 97(5):893-898. PubMed ID: 29453624
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Genomic variation in the MAP3K5 gene is associated with β-thalassemia disease severity and hydroxyurea treatment efficacy.
    Tafrali C; Paizi A; Borg J; Radmilovic M; Bartsakoulia M; Giannopoulou E; Giannakopoulou O; Stojiljkovic-Petrovic M; Zukic B; Poulas K; Stavrou EF; Lambropoulou P; Kourakli A; Felice AE; Papachatzopoulou A; Philipsen S; Pavlovic S; Georgitsi M; Patrinos GP
    Pharmacogenomics; 2013 Apr; 14(5):469-83. PubMed ID: 23556445
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comparative study of pulmonary circulation and myocardial function in patients with β-thalassemia intermedia with and without hydroxyurea, a case-control study.
    Amoozgar H; Farhani N; Khodadadi N; Karimi M; Cheriki S
    Eur J Haematol; 2011 Jul; 87(1):61-7. PubMed ID: 21447009
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The bone density of thalassemic patients of Boo Ali Sina Hospital, Sari, Iran in 2002 does hydroxyurea help?
    Kosaryan M; Zadeh MF; Shahi VK
    Pediatr Endocrinol Rev; 2004 Dec; 2 Suppl 2():303-6. PubMed ID: 16462716
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Hodgkin's disease in a child with sickle cell disease treated with hydroxyurea.
    Moschovi M; Psychou F; Menegas D; Tsangaris GT; Tzortzatou-Stathopoulou F; Nicolaidou P
    Pediatr Hematol Oncol; 2001 Sep; 18(6):371-6. PubMed ID: 11554231
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
    Yawn BP; Buchanan GR; Afenyi-Annan AN; Ballas SK; Hassell KL; James AH; Jordan L; Lanzkron SM; Lottenberg R; Savage WJ; Tanabe PJ; Ware RE; Murad MH; Goldsmith JC; Ortiz E; Fulwood R; Horton A; John-Sowah J
    JAMA; 2014 Sep; 312(10):1033-48. PubMed ID: 25203083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.